Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced a significant development in its partnership with Nestlé Health Science—a non-binding memorandum of understanding whereby Nestlé Health Science will acquire certain tangible and intangible assets related to VOWST (fecal microbiota spores, live-brpk) capsules. This pivotal transaction will grant Nestlé Health Science full control over the development, commercialization, and […]
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The biologics license application (BLA) of the American microbiome therapeutics company for SER-109 has been given a prescription drug user fee act (PDUFA) action […]
Private equity firm Butterfly has signed a deal to divest a majority stake in Orgain, a plant-based functional nutrition platform, to Nestlé Health Science. The financial terms of the deal were not disclosed. Butterfly and Orgain’s Founder and CEO – Dr. Andrew Abraham will retain a significant minority stake in the company that makes protein-based […]
Nestlé has signed a deal worth $5.75 billion with KKR to acquire core brands of Bountiful, a US manufacturer of vitamins and nutritional supplements. Included in the deal are Bountiful’s brands – Nature’s Bounty, Solgar, Osteo Bi-Flex, and Puritan’s Pride and also its US private label business. Nestlé will integrate the acquired brands into Nestlé […]
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). According to the US-based biotech company, SER-301 is an oral fermented microbiome therapeutic designed for dampening the unusual gastrointestinal inflammation central to ulcerative colitis and promote clinical remission in […]
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected to help the Swiss conglomerate’s subsidiary Nestlé Health Science and Aimmune Therapeutics to create a global leader in the prevention […]
Nestlé Health Science (NHSc) has agreed to acquire a majority stake in Vital Proteins, a US collagen brand and a lifestyle and wellness platform that manufactures supplements, beverages, and food products. Financial terms of the deal were not disclosed. The closing of the transaction is subject to regulatory approval. Considered to be the most abundant […]
Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured an additional equity investment of $200 million from Nestlé Health Science. Based in California, Aimmune Therapeutics has been focused on the development and commercialization of treatments for potentially life-threatening food […]
